SEC 13F Intelligence

Managers / Q2 2023 · view latest →

SECTORAL ASSET MANAGEMENT INC

CIK 0001274413 · 1010 SHERBROOKE ST., WEST, SUITE 1610, MONTREAL, A8, H3A 2R7 · 514 849 8777

Reported Value
$600M
Q2 2023
Positions
121
Filings on Record
30
2019–present window
Filed
Aug 11, 2023
original filing

Summary

Sectoral Asset Management Inc reported $600M in U.S.-listed holdings across 121 positions for Q2 2023.

Its largest position, R1 Rcm, represents 2.5% of the portfolio.

Compared with Q1 2023, the fund opened 15 new positions and exited 12.

Portfolio Metrics

Turnover
+14.4%
vs prior filed quarter
Top-10 Concentration
+21.7%
share of reported value
Largest Position
+2.5%
R1 Rcm
New / Exited
15 / 12
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $736MQ4 ’18Q1 ’19: $831MQ2 ’19: $836MQ3 ’19: $580MQ4 ’19: $670MQ4 ’19Q1 ’20: $521MQ2 ’20: $1.1BQ3 ’20: $1.2BQ4 ’20: $1.4BQ4 ’20Q1 ’21: $1.3BQ2 ’21: $1.2BQ3 ’21: $1.2BQ4 ’21: $664MQ4 ’21Q1 ’22: $563MQ2 ’22: $496MQ3 ’22: $508MQ4 ’22: $517MQ4 ’22Q1 ’23: $520MQ2 ’23: $600MQ3 ’23: $514MQ4 ’23: $232MQ4 ’23Q1 ’24: $254MQ2 ’24: $246MQ3 ’24: $169MQ4 ’24: $150MQ4 ’24Q1 ’25: $128MQ2 ’25: $151MQ3 ’25: $162MQ4 ’25: $125MQ4 ’25Q1 ’26: $121Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 88.6%Other: 10.3%ADR: 0.9%ETP: 0.3%
  • Common Stock · 88.6% · $532M
  • Other · 10.3% · $62M
  • ADR · 0.9% · $5M
  • ETP · 0.3% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MLTXMOONLAKE IMMUNOTHERANEW+184.6K184.6K+$9M$9M
MMSIMERIT MEDICAL SYSNEW+76.0K76.0K+$6M$6M
CNMDCONMED CORPNEW+45.5K45.5K+$6M$6M
ARWRARROWHEAD PHARMACEUTNEW+143.9K143.9K+$5M$5M
GKOSGLAUKOS CORPNEW+69.0K69.0K+$5M$5M
ACELYRIN INCNEW+201.0K201.0K+$4M$4M
OCULOCULAR THERAPEUTIXNEW+802.7K802.7K+$4M$4M
PODDINSULET CORPNEW+12.5K12.5K+$4M$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2023

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1R1 RCM INCCOM2.49%$15M809.2K
2EVHEVOLENT HEALTH INChistory →CL A2.47%$15M488.1K
3PRVAPRIVIA HEALTH GROUPhistory →COM2.21%$13M506.6K
4APLSUSDAPELLIS PHARMACEUTIChistory →COM2.19%$13M143.9K
5RDNTRADNET INChistory →COM2.17%$13M398.6K
6BMRNBIOMARIN PHARMAC INChistory →COM2.15%$13M148.4K
7OPCHOPTION CARE HEALTHhistory →COM2.11%$13M390.0K
8ICON PLCSHS2.00%$12M48.0K
9ATRCATRICURE INChistory →COM1.97%$12M239.5K
10HQYHEALTHEQUITY INChistory →COM1.93%$12M183.4K
11LLYLILLY ELI & COhistory →COM1.86%$11M23.8K
12UNHUNITEDHEALTH GRP INChistory →COM1.84%$11M22.9K
13IM8NINSMED INChistory →COM1.82%$11M517.8K
14MLYSMINERALYS THERAPEUTIhistory →COM1.75%$10M614.7K
15PROTHENA CORP PLCSHS1.73%$10M151.8K
16JNJJOHNSON & JOHNSONhistory →COM1.71%$10M62.1K
17TMCITREACE MED CONCEPThistory →COM1.62%$10M379.4K
18PTCTPTC THERAPEUTICS Ihistory →COM1.57%$9M231.7K
19MLTXMOONLAKE IMMUNOTHERAhistory →CL A1.57%$9M184.6K
20AM6AMICUS THERAPEUTICShistory →COM1.53%$9M729.9K
21INARI MED INCCOM1.48%$9M153.0K
222655787DBLUEPRINT MEDICINEShistory →COM1.44%$9M136.8K
23SPRYARS PHARMACEUTICALShistory →COM1.40%$8M1.26M
24AMLXAMYLYX PHARMACEUTIChistory →COM1.39%$8M387.3K
25LNTHLANTHEUS HLDGS INChistory →COM1.38%$8M98.7K
26IMGNEURIMMUNOGEN INChistory →COM1.37%$8M436.4K
27INSPINSPIRE MED SYS INChistory →COM1.30%$8M24.0K
28AGILITI INCCOM1.29%$8M469.3K
29ITCIEURINTRA CELLULAR THERAhistory →COM1.27%$8M119.9K
30ALKERMES PLCSHS1.26%$8M242.2K
31THCTENET HEALTHCAREhistory →COM1.24%$7M91.5K
32DNLIDENALI THERAPEUTICShistory →COM1.21%$7M245.3K
33RCUSARCUS BIOSCIENCEShistory →COM1.20%$7M354.5K
34TVTXTRAVERE THERAPEUTICShistory →COM1.11%$7M435.3K
35ZNTLZENTALIS PHARMACEUhistory →COM1.10%$7M234.0K
36AXNX*AXONICS INChistory →COM1.08%$6M128.0K
37MMSIMERIT MEDICAL SYShistory →COM1.06%$6M76.0K
38MRKMERCK & CO INChistory →COM1.06%$6M55.0K
39AMGNAMGEN INChistory →COM1.05%$6M28.3K
40GRTXGALERA THERAPEUTIChistory →COM1.04%$6M2.01M
41CNMDCONMED CORPhistory →COM1.03%$6M45.5K
42SRPTSAREPTA THERAPEUTICShistory →COM1.00%$6M52.4K
43OLMAOLEMA PHARMACEUTICALCOM0.98%$6M648.4K
44PFEPFIZER INCCOM0.96%$6M157.4K
45ALNYALNYLAM PHARMACUETCLCOM0.94%$6M29.8K
46VERAVERA THERAPEUTICSCL A0.94%$6M351.6K
47KARUNA THERAPEUTICSCOM0.93%$6M25.7K
48REPLREPLIMUNE GROUP INCCOM0.92%$6M238.5K
49ABTABBOTT LABSCOM0.91%$5M50.2K
50PCVXVAXCYTE INCCOM0.91%$5M109.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$121M77May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$125M74Feb 9, 202613F-HRchanges · EDGAR ↗
Q3 2025$162M82Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$151M94Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$128M84May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$150M86Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$169M90Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$246M97Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$254M92May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$232M104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$514M123Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$600M121Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$520M118May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$517M120Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$508M109Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$496M112Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$563M106May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$664M108Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.2B127Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.3B113May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.4B97Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.2B88Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B191Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$521M65May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$670M65Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$580M63Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$836M92Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$831M106May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$736M104Feb 12, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.